180 related articles for article (PubMed ID: 34392598)
1. Treatment induced clearance of hepatitis E viruses by interferon-lambda in liver-humanized mice.
Sari G; Mulders CE; Zhu J; van Oord GW; Feng Z; Kreeft-Voermans JJC; Boonstra A; Vanwolleghem T
Liver Int; 2021 Dec; 41(12):2866-2873. PubMed ID: 34392598
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha treatment rapidly clears Hepatitis E virus infection in humanized mice.
van de Garde MDB; Pas SD; van Oord GW; Gama L; Choi Y; de Man RA; Boonstra A; Vanwolleghem T
Sci Rep; 2017 Aug; 7(1):8267. PubMed ID: 28811492
[TBL] [Abstract][Full Text] [Related]
3. The Viral ORF3 Protein Is Required for Hepatitis E Virus Apical Release and Efficient Growth in Polarized Hepatocytes and Humanized Mice.
Sari G; Zhu J; Ambardekar C; Yin X; Boonstra A; Feng Z; Vanwolleghem T
J Virol; 2021 Nov; 95(23):e0058521. PubMed ID: 34523963
[TBL] [Abstract][Full Text] [Related]
4. Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient.
Kamar N; Abravanel F; Garrouste C; Cardeau-Desangles I; Mansuy JM; Weclawiak H; Izopet J; Rostaing L
Nephrol Dial Transplant; 2010 Aug; 25(8):2792-5. PubMed ID: 20494897
[TBL] [Abstract][Full Text] [Related]
5. ISG15 Modulates Type I Interferon Signaling and the Antiviral Response during Hepatitis E Virus Replication.
Sooryanarain H; Rogers AJ; Cao D; Haac MER; Karpe YA; Meng XJ
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724761
[TBL] [Abstract][Full Text] [Related]
6. Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation.
Allweiss L; Gass S; Giersch K; Groth A; Kah J; Volz T; Rapp G; Schöbel A; Lohse AW; Polywka S; Pischke S; Herker E; Dandri M; Lütgehetmann M
J Hepatol; 2016 May; 64(5):1033-1040. PubMed ID: 26805671
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis E Virus (HEV) Genotype 3 Infection of Human Liver Chimeric Mice as a Model for Chronic HEV Infection.
van de Garde MD; Pas SD; van der Net G; de Man RA; Osterhaus AD; Haagmans BL; Boonstra A; Vanwolleghem T
J Virol; 2016 May; 90(9):4394-401. PubMed ID: 26889028
[TBL] [Abstract][Full Text] [Related]
8. Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection.
Zhou X; Xu L; Wang W; Watashi K; Wang Y; Sprengers D; de Ruiter PE; van der Laan LJ; Metselaar HJ; Kamar N; Peppelenbosch MP; Pan Q
J Viral Hepat; 2016 Apr; 23(4):294-304. PubMed ID: 26620360
[TBL] [Abstract][Full Text] [Related]
9. Positive Regulation of Hepatitis E Virus Replication by MicroRNA-122.
Haldipur B; Bhukya PL; Arankalle V; Lole K
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540601
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C.
Ramos EL
J Interferon Cytokine Res; 2010 Aug; 30(8):591-5. PubMed ID: 20645873
[TBL] [Abstract][Full Text] [Related]
11. Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver.
Sayed IM; Verhoye L; Cocquerel L; Abravanel F; Foquet L; Montpellier C; Debing Y; Farhoudi A; Wychowski C; Dubuisson J; Leroux-Roels G; Neyts J; Izopet J; Michiels T; Meuleman P
Gut; 2017 May; 66(5):920-929. PubMed ID: 27006186
[TBL] [Abstract][Full Text] [Related]
12. Revisiting the Mongolian Gerbil Model for Hepatitis E Virus by Reverse Genetics.
Xu LD; Zhang F; Chen C; Peng L; Luo WT; Chen R; Xu P; Huang YW
Microbiol Spectr; 2022 Apr; 10(2):e0219321. PubMed ID: 35230152
[TBL] [Abstract][Full Text] [Related]
13. Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma.
Sayed IM; Foquet L; Verhoye L; Abravanel F; Farhoudi A; Leroux-Roels G; Izopet J; Meuleman P
Antiviral Res; 2017 May; 141():150-154. PubMed ID: 28232247
[TBL] [Abstract][Full Text] [Related]
14. Suppression of interferon-α signaling by hepatitis E virus.
Dong C; Zafrullah M; Mixson-Hayden T; Dai X; Liang J; Meng J; Kamili S
Hepatology; 2012 May; 55(5):1324-32. PubMed ID: 22183878
[TBL] [Abstract][Full Text] [Related]
15. Rat Hepatitis E Virus as Cause of Persistent Hepatitis after Liver Transplant.
Sridhar S; Yip CCY; Wu S; Cai J; Zhang AJ; Leung KH; Chung TWH; Chan JFW; Chan WM; Teng JLL; Au-Yeung RKH; Cheng VCC; Chen H; Lau SKP; Woo PCY; Xia NS; Lo CM; Yuen KY
Emerg Infect Dis; 2018 Dec; 24(12):2241-2250. PubMed ID: 30457530
[TBL] [Abstract][Full Text] [Related]
16. Antiviral therapy in chronic hepatitis E: a systematic review.
Peters van Ton AM; Gevers TJ; Drenth JP
J Viral Hepat; 2015 Dec; 22(12):965-73. PubMed ID: 25760481
[TBL] [Abstract][Full Text] [Related]
17. Immunocompromised rabbit model of chronic HEV reveals liver fibrosis and distinct efficacy of different vaccination strategies.
He Q; Zhang F; Shu J; Li S; Liang Z; Du M; Liu X; Liu T; Li M; Yin X; Pan Q; Lu F; Wang L; Wang L
Hepatology; 2022 Sep; 76(3):788-802. PubMed ID: 35278241
[TBL] [Abstract][Full Text] [Related]
18. Identification of structurally re-engineered rocaglates as inhibitors against hepatitis E virus replication.
Praditya DF; Klöhn M; Brüggemann Y; Brown LE; Porco JA; Zhang W; Kinast V; Kirschning A; Vondran FWR; Todt D; Steinmann E
Antiviral Res; 2022 Aug; 204():105359. PubMed ID: 35728703
[TBL] [Abstract][Full Text] [Related]
19. Robust hepatitis E virus infection and transcriptional response in human hepatocytes.
Todt D; Friesland M; Moeller N; Praditya D; Kinast V; Brüggemann Y; Knegendorf L; Burkard T; Steinmann J; Burm R; Verhoye L; Wahid A; Meister TL; Engelmann M; Pfankuche VM; Puff C; Vondran FWR; Baumgärtner W; Meuleman P; Behrendt P; Steinmann E
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1731-1741. PubMed ID: 31896581
[TBL] [Abstract][Full Text] [Related]
20. The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo.
Todt D; Moeller N; Praditya D; Kinast V; Friesland M; Engelmann M; Verhoye L; Sayed IM; Behrendt P; Dao Thi VL; Meuleman P; Steinmann E
Antiviral Res; 2018 Sep; 157():151-158. PubMed ID: 30036559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
